On August 5, 2021 IntelGenx Technologies Corp. (the "Company") reported that closed an offering by way of private placement in the United States (the "Private Placement") of unsecured convertible notes (the "Notes"). Each Note bears interest at a rate of 8% (payable quarterly, in arrears, with the first payment being due on September 1, 2021), matures on July 31, 2025 and is convertible, after a six-month holding period from the Initial Closing Date, into common stock of the Company (the "Common Shares") at a conversion price of $0.40 per share (the "Conversion Price") (Filing, 8-K, IntelGenx, AUG 5, 2021, View Source [SID1234586309]). The Notes issued on the Closing Date pursuant to the Private Placement were issued for gross proceeds of approximately $2.1 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company intends to use the proceeds from the Private Placement for its Montelukast study, working capital and the Company’s expenses of the Offering.

Cantone Research, Inc. ("Cantone") acted as placement agent in respect of the Private Placement.

In connection with the Private Placement, Cantone is entitled to a cash commission of approximately $199,525 and non-transferable warrants entitling Cantone to purchase 613,000 Common Shares (the "Placement Agent Warrants"). The Placement Agent Warrants are exercisable into Common Shares at the Conversion Price and will expire in two years from the Closing Date.

On August 5, 2021 iCo Therapeutics Inc. ("iCo" or the "Company") (TSXV: iCo) (OTCQB: iCoTF) reported that the at an annual and special meeting of the Company held on August 3, 2021, shareholder of the Company have approved, among other matters, iCo’s proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos") (Press release, iCo Therapeutics, AUG 5, 2021, View Source [SID1234586216]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The, the Company expects trading of the shares of the combined company to begin trading on the TSX Venture Exchange as Satellos Bioscience Inc. under the symbol MSCL during the week of August 9, 2021.

William Jarosz, the CEO of iCo noted, "The Satellos transaction was approved by 98.5% of the shareholders voting at the annual and special meeting of the shareholders. The shareholders recognized the tremendous value that the Satellos assets have brought to the business combination. We are grateful for this support and will work diligently going forward to ensure that this support is warranted. We are very excited about what lies ahead for iCo."

Exelixis has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 5, 2021 Prescient Therapeutics Limited (ASX:PTX) reported that it is engaged in developing a robust drug pipeline comprising CAR-T and targeted therapies (PTX-100 & PTX-200) for various challenging cancers with unmet medical needs (Press release, Prescient Therapeutics, AUG 5, 2021, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-in-a-sweet-spot-with-significant-progress-in-multiple-cancer-programs [SID1234586072]). The personalised medicine approaches of the Company seek to improve patient outcomes in combating cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Furthermore, Prescient is working to rapidly expand the application of universal CAR-T therapies capable of addressing difficult-to-treat cancers.

On 4 August 2021, the Company announced its participation in Reach Markets’ ‘The Insider: Meet the CEO’ session, where PTX gave a presentation highlighting key developments in multiple cancer programs.

Prescient’s innovative pipeline in personalised medicine, Source: PTX Investor Presentation, 4 August 2021

ALSO READ: Prescient ends June quarter with notable progress in cancer programs and a healthy financial position

PTX-100 showed an excellent safety profile and exhibited encouraging activity in Phase 1b trial
In the Phase 1b basket trial, PTX-100 demonstrated an impressive safety profile and was well tolerated at the highest dose of 2,000mg/m2. In addition, no serious adverse events (SAEs) related to PTX-100 were observed during the study. Notably, the drug also exhibited clinical benefit in two T cell lymphoma (TCL) patients with aggressive disease that had not responded to 3-5 prior therapies.

The Company is now planning to conduct an expansion cohort study of PTX-100 concentrating on the treatment of TCL with a possibility of subsequent registration study. Currently, the Company anticipates enrolling up to 12 patients with T cell lymphoma (mainly Peripheral T-Cell Lymphoma or PTCL), which represents an area of considerable unmet need.

RELATED ARTICLE: Prescient takes its PTX-100 trial to next level after Phase 1b success

PTX-200 Phase 1b trial underway: Acute myeloid leukemia (AML)
The PTX-200 AML study is spearheaded by world-renowned leukemia specialist Professor Jeffrey Lancet at Moffitt Cancer Center and Dr Tara Lin at the University of Kansas Medical Center (KUMC).

Initially, PTX-200 was tested for 25 mg/m2. Having proved its safety, the AML study was advanced to a higher dose of to 35 mg/m2. The Company highlighted that the three patients treated with the 35 mg/m2 dose had achieved complete responses in the study so far. Currently, PTX is screening the second cohort at 45 mg/m2.

Moreover, PTX-200 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration.

RELATED ARTICLE: Prescient Therapeutics’ (ASX:PTX) AML trial progresses to next dosing level

OmniCAR- A universal next-generation CAR-T
Prescient is developing next-generation products in-house. In January 2021, the oncology player disclosed its three OmniCAR programs-

In June, the Company completed another CAR-T milestone with the completion of manufacturing and delivery of crucial components of the OmniCAR platform. In addition, PTX highlighted that the binders against various cancer targets, including CLL-1, CD33, Her2, and EGFRviii, were produced by a US-based leading antibody manufacturer.

Additionally, in-silico evaluation confirmed the non-immunogenic profile of these crucial components. The results demonstrated that OmniCAR’s binding system components – SpyTag and SpyCatcher – have very low immunogenicity, lower than a panel of humanised therapeutic antibodies already approved for human use.

OnmiCAR also offers collaboration and licensing opportunities for third parties via partnerships based on targets, specific constructs as well as cell types.

Source: PTX Investor Presentation, 4 August 2021

RELATED ARTICLES:

Prescient Therapeutics reaches a major CAR-T manufacturing milestone
Positive results from immunogenicity testing send Prescient’s shares higher
Cell Therapy Enhancements (CTE) programs

Prescient has several other initiatives in progress to develop new cell therapy programs. The new programs overcome the efficiency challenges confronted by other CAR-T therapies.

CTE programs are now being undertaken at Peter MacCallum Cancer Centre, another sign of the fast-developing relationship between the two organisations. Notably, Prescient would have 100% ownership of intellectual property (IP) generated from the ongoing research on cell therapy enhancement programs.

On 4 August 2021, PTX shares closed at AU$0.185, up by 5.714%.

On August 5, 2021 Varian, a Siemens Healthineers company, reported that cancer patients in Australia will be the first in the world to benefit from streamlined, coordinated cancer care facilitated by an upcoming release of the ARIA oncology information system (OIS) with new multi-disciplinary functionality (Press release, Varian Medical Systems, AUG 5, 2021, View Source [SID1234586060]). Australia’s Icon Group will become the first in the world to deploy this new system, which is scheduled for release in Australia and other global sites in early 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Icon plans to go live with its first location in 2022. After a successful deployment, the new ARIA system will serve as Icon’s next-generation platform for enhancing clinical operations, and further deployments at other Icon sites will commence. The longer-term plan is to install this integrated solution across Icon’s global footprint of 44 locations over several years.

Icon will also be the first in the Australian and Asia/Pacific regions to deploy Varian’s Noona electronic patient-reported outcomes (ePRO) solution, a digital application that enables real-time patient engagement and seamlessly integrates with the new ARIA release.

Mark Middleton, CEO, Icon Group, said, "Icon is delighted to once again be at the forefront of technology evolution alongside Varian. As a global provider of comprehensive cancer care, having systems that address the breadth of our operations is vital to seamless patient care. Varian’s new solution will ensure we continue to advance clinical efficiency, quality assurance, and information security, and it will enhance our team’s ability to focus on the most important part of their day – their patients."

Icon, a long-time and experienced user of ARIA for the management of radiation oncology, is expanding its use of the software to also manage medical oncology. By adding the Noona ePRO application, Icon will be able to integrate patient-reported outcomes data into its patient care practices.

"Icon has chosen a combination of integrated tools that will provide its clinical teams with multiple benefits, including efficient and standardized clinical workflows, a cloud-based software-as-a-service operations model, and the ability to use real-time symptom information to manage the patient’s cancer treatment journey more proactively," said Kenneth Tan, president, Asia Pacific and Japan, Varian. "We are proud to be working with Icon Group, a dedicated group of professionals who are committed to bringing the latest innovations to their patients."

ARIA is Varian’s comprehensive oncology information system for managing clinical, administrative, and financial processes in comprehensive cancer treatment environments. It interconnects clinical functions and provides clinical staff members with up-to-the-minute information for making important clinical decisions quickly at every point in a patient’s course of treatment.